Diabetes Mellitus News and Research

RSS
Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Consumption of caffeinated coffee and alcohol reduces risk of contracting late onset diabetes

Consumption of caffeinated coffee and alcohol reduces risk of contracting late onset diabetes

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

Phase 3 clinical study demonstrates efficacy of metformin therapy in type 2 diabetes

Phase 3 clinical study demonstrates efficacy of metformin therapy in type 2 diabetes

Takeda underscores commitment to ACTOS following FDA and EMA announcements for rosiglitazone

Takeda underscores commitment to ACTOS following FDA and EMA announcements for rosiglitazone

Type 1 diabetes, early recognition, telltale signs

Type 1 diabetes, early recognition, telltale signs

Tolerx presents otelixizumab preclinical research at 46th EASD

Tolerx presents otelixizumab preclinical research at 46th EASD

Novartis' SOM230 reduces cortisol levels in Cushing's disease patients

Novartis' SOM230 reduces cortisol levels in Cushing's disease patients

PROMUS Element Stent receives expanded indications approval for high-risk diabetic and AMI patient groups

PROMUS Element Stent receives expanded indications approval for high-risk diabetic and AMI patient groups

ChemoCentryx presents CCX140 clinical data at EASD

ChemoCentryx presents CCX140 clinical data at EASD

Annals of Internal Medicine publishes GRACE study data on HIV therapy

Annals of Internal Medicine publishes GRACE study data on HIV therapy

FDA Advisory Committee recommends approval of dabigatran etexilate for stroke prevention in AFib patients

FDA Advisory Committee recommends approval of dabigatran etexilate for stroke prevention in AFib patients

Harbor BioSciences granted US patent for Triolex metabolic disease and anti-inflammation drug candidate

Harbor BioSciences granted US patent for Triolex metabolic disease and anti-inflammation drug candidate

Dapagliflozin added to glimepiride therapy reduces HbA1c in adult type 2 diabetes patients

Dapagliflozin added to glimepiride therapy reduces HbA1c in adult type 2 diabetes patients

Phase III trial results of lixisenatide for type 2 diabetes presented at 46th EASD

Phase III trial results of lixisenatide for type 2 diabetes presented at 46th EASD

Atherotech Diagnostics publishes article on advantages of cholesterol testing

Atherotech Diagnostics publishes article on advantages of cholesterol testing

FDA reviews Actos drug for bladder cancer risk

FDA reviews Actos drug for bladder cancer risk

HHS awards grant to develop patient-centered outcomes research

HHS awards grant to develop patient-centered outcomes research

Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer

Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer

FDA grants Arcion's ARC-4558 Fast Track designation for pain involved in Painful Diabetic Neuropathy

FDA grants Arcion's ARC-4558 Fast Track designation for pain involved in Painful Diabetic Neuropathy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.